Loading...
In the LEADER trial, 9340 type 2 diabetic adults at high cardiovascular risk received the glucagon-like peptide-1 (GLP-1) analog liraglutide (Victoza) or placebo for an average of 4 years. (NEJM JW Gen Med Jul 15 2016 and N Engl J Med 2016; 375:311). In the trial's initial report, risk for gallstone-related disease was significantly higher with liraglutide than with placebo (3.1% vs. 1.9%; P<0.001).
Now, researchers have explored this issue in more detail, with key findings as follows:
No striking differences were noted in baseline characteristics of patients who developed gallstone events versus patients who did not.
In each of various subsets of patients with incident gallstone disease (i.e., uncomplicated stones, complicated stones, cholecy…